Report
Christophe-Raphaël Ganet

bioMerieux : Pretty encouraging prospects, but the valuation is fairly high

>A very reassuring tone on the guidance for 2019 - Key takeaways from our road show with management: 1/ a reassuring stance and even a concerted and optimistic tone on the growth outlook for H2 2019: H1 came in at 5.5% l-f-l, and the guidance for 7/8.5% is maintained; this implies over 8% l-f-l in H2. Growth is set to be based on: i/ a return to normal for molecular biology / BioFire, as begun in Q2 (Q2: +29% vs Q1: +10% l-f-l), ii/ an end to the temporary diffic...
Underlying
bioMerieux S.A.

Co. specializes in the field of in vitro diagnostics for clinical and industrial applications. Co. designs, develops, manufactures and markets systems used in: Clinical Applications (the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancers, based on the analysis of biological samples such as blood, saliva or urine); and Industrial Applications (microbiological analysis of samples of finished or semi-finished products (or of the environment), chiefly in the food processing and biopharmaceutical industries), detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Christophe-Raphaël Ganet

Other Reports on these Companies
Other Reports from Oddo BHF
Other Reports from these Analysts
Alain William ...
  • Alexandre Iatrides
  • Christophe-Raphaël Ganet
  • Geoffroy Michalet
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Olfa Taamallah
  • Pierre Tegner
  • Sebastien Malafosse
  • Yan Derocles

ResearchPool Subscriptions

Get the most out of your insights

Get in touch